At the news
? NEUTRALIMPACT 5/10 8-K filed Jun 11, 2026 at 16:44 ET
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash through a tender offer and subsequent merger, closing on June 11, 2026. A total of 43,152,532 shares (approximately 77.8% of outstanding) were validly tendered. As a result, KalVista became a wholly owned subsidiary of Chiesi, its common stock ceased trading on Nasdaq, and all remaining shares were converted into the right to receive the same $27.00 per share cash consideration.
- Tender offer expired June 10, 2026; 43,152,532 shares (77.8%) validly tendered
- Merger completed June 11, 2026 via Section 251(h) of Delaware law without stockholder vote
- Stock consideration: $27.00 per share in cash
- KalVista common stock delisted from Nasdaq Global Market effective prior to June 11, 2026 trading
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access